Analysts have clear opinions on NLTX.

There are 2 analysts on the Wall offering 12 month price targets for Neoleukin Therapeutics in the last 3 months. The average price target is $20.00 with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 88.68% increase from the last price of $10.60.
Neoleukin Therapeutics, Inc. (NLTX) is followed by 2 analysts on the street.

null from rates it a .

Similarly, null of a with a target of .

The consensus on the street is null.

What does Neoleukin Therapeutics, Inc.(NLTX) do ?
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Neoleukin Therapeutics, Inc. (NLTX) Insider Trades

Multiple company employees have indulged in significant insider trading. Neoleukin Therapeutics, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Pres, CEO, Drachman Jonathan G : P – Purchase(+$999,995) of NLTX in the trading session of 2019-12-20.

Dir Baker Bros. Advisors LP : P – Purchase(+$25,347,353) of NLTX in the trading session of 2019-12-20.

See Remarks Drachman Jonathan G : P – Purchase(+$781,747) of Neoleukin Therapeutics, Inc. in the trading session of 2019-09-09.

Looking for stocks just like NLTX?

Based on Wall Street analyst research, several stocks are similar to NLTX
They are:
– URGN [Info can be found here: ]
– AKBA [Info can be found here: ]
– ARDX [Info can be found here: ]